Shares of Synlogic (NASDAQ:SYBX) rose 2.7% in pre-market trading after the company reported Q1 results.
Earnings per share were up 9.80% year over year to ($0.46), which missed the estimate of ($0.43).
Revenue of $100,000 less by 70.41% year over year, which missed the estimate of $450,000.
Earnings guidance hasn't been issued by the company for now.
Synlogic hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 08, 2020
Webcast URL: https://edge.media-server.com/mmc/p/o38dmqqm
Recent Stock Performance
52-week high: $10.01
Company's 52-week low was at $1.35
Price action over last quarter: Up 44.65%
Synlogic Inc is a biopharmaceutical company focused on advancing the drug discovery and development platform for Synthetic Biotic medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer.